AURA
NASDAQ · Biotechnology
Aura Biosciences Inc
$6.55
-0.03 (-0.46%)
Open$6.58
Previous Close$6.58
Day High$6.77
Day Low$6.45
52W High$7.73
52W Low$4.35
Volume—
Avg Volume243.0K
Market Cap361.97M
P/E Ratio—
EPS$-1.93
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
+395.6% upside
Current
$6.55
$6.55
Target
$32.46
$32.46
$26.53
$32.46 avg
$55.40
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 444.35M | 423.64M | 422.21M |
| Net Income | 17.80M | 13.08M | 16.40M |
| Profit Margin | 4.0% | 3.1% | 3.9% |
| EBITDA | 20.20M | 21.97M | 19.97M |
| Free Cash Flow | 12.95M | 9.01M | 11.94M |
| Rev Growth | +9.8% | +0.1% | +6.7% |
| Debt/Equity | 1.09 | 1.02 | 0.95 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $207.18 | +0.96% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.93 | +1.58% | 24.4 | 188.06B |
| GILD | Gilead Sciences Inc | $138.26 | +0.11% | 20.0 | 170.34B |
| VRTX | Vertex Pharmaceuticals Inc | $454.97 | +1.42% | 29.2 | 115.53B |
| REGN | Regeneron Pharmaceuticals | $749.47 | +1.05% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.70 | +6.70% | 139.7 | 43.84B |